These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 21217077)

  • 1. Factor VIII A3 domain substitution N1922S results in hemophilia A due to domain-specific misfolding and hyposecretion of functional protein.
    Summers RJ; Meeks SL; Healey JF; Brown HC; Parker ET; Kempton CL; Doering CB; Lollar P
    Blood; 2011 Mar; 117(11):3190-8. PubMed ID: 21217077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Missense mutations near the N-glycosylation site of the A2 domain lead to various intracellular trafficking defects in coagulation factor VIII.
    Wei W; Zheng C; Zhu M; Zhu X; Yang R; Misra S; Zhang B
    Sci Rep; 2017 Mar; 7():45033. PubMed ID: 28327546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mild hemophilia A caused by increased rate of factor VIII A2 subunit dissociation: evidence for nonproteolytic inactivation of factor VIIIa in vivo.
    Pipe SW; Eickhorst AN; McKinley SH; Saenko EL; Kaufman RJ
    Blood; 1999 Jan; 93(1):176-83. PubMed ID: 9864159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modification of interdomain interfaces within the A3C1C2 subunit of factor VIII affects its stability and activity.
    Wakabayashi H; Fay PJ
    Biochemistry; 2013 Jun; 52(22):3921-9. PubMed ID: 23659383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mild hemophilia A patient with novel Pro1809Leu mutation develops an anti-C2 antibody inhibiting allogeneic but not autologous factor VIII activity.
    Yada K; Nogami K; Takeyama M; Ogiwara K; Wakabayashi H; Shima M
    J Thromb Haemost; 2015 Oct; 13(10):1843-53. PubMed ID: 26278069
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Replacing the factor VIII C1 domain with a second C2 domain reduces factor VIII stability and affinity for factor IXa.
    Wakabayashi H; Fay PJ
    J Biol Chem; 2013 Oct; 288(43):31289-97. PubMed ID: 24030831
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Factor VIII C2 domain missense mutations exhibit defective trafficking of biologically functional proteins.
    Pipe SW; Kaufman RJ
    J Biol Chem; 1996 Oct; 271(41):25671-6. PubMed ID: 8810344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and functional requirement of Cu(I) and its ligands within coagulation factor VIII.
    Tagliavacca L; Moon N; Dunham WR; Kaufman RJ
    J Biol Chem; 1997 Oct; 272(43):27428-34. PubMed ID: 9341195
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A human antibody directed to the factor VIII C1 domain inhibits factor VIII cofactor activity and binding to von Willebrand factor.
    Jacquemin M; Benhida A; Peerlinck K; Desqueper B; Vander Elst L; Lavend'homme R; d'Oiron R; Schwaab R; Bakkus M; Thielemans K; Gilles JG; Vermylen J; Saint-Remy JM
    Blood; 2000 Jan; 95(1):156-63. PubMed ID: 10607698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of the antigenicity of factor VIII toward complex inhibitory antibody plasmas using multiply-substituted hybrid human/porcine factor VIII molecules.
    Barrow RT; Healey JF; Gailani D; Scandella D; Lollar P
    Blood; 2000 Jan; 95(2):564-8. PubMed ID: 10627463
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifactor VIII antibody inhibiting allogeneic but not autologous factor VIII in patients with mild hemophilia A.
    Peerlinck K; Jacquemin MG; Arnout J; Hoylaerts MF; Gilles JG; Lavend'homme R; Johnson KM; Freson K; Scandella D; Saint-Remy JM; Vermylen J
    Blood; 1999 Apr; 93(7):2267-73. PubMed ID: 10090936
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A 110-amino acid region within the A1-domain of coagulation factor VIII inhibits secretion from mammalian cells.
    Marquette KA; Pittman DD; Kaufman RJ
    J Biol Chem; 1995 Apr; 270(17):10297-303. PubMed ID: 7730335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioengineering of coagulation factor VIII for improved secretion.
    Miao HZ; Sirachainan N; Palmer L; Kucab P; Cunningham MA; Kaufman RJ; Pipe SW
    Blood; 2004 May; 103(9):3412-9. PubMed ID: 14726380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The molecular basis for cross-reacting material-positive hemophilia A due to missense mutations within the A2-domain of factor VIII.
    Amano K; Sarkar R; Pemberton S; Kemball-Cook G; Kazazian HH; Kaufman RJ
    Blood; 1998 Jan; 91(2):538-48. PubMed ID: 9427707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antigenicity of putative phospholipid membrane-binding residues in factor VIII.
    Barrow RT; Healey JF; Jacquemin MG; Saint-Remy JM; Lollar P
    Blood; 2001 Jan; 97(1):169-74. PubMed ID: 11133757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor.
    Gish JS; Jarvis L; Childers KC; Peters SC; Garrels CS; Smith IW; Spencer HT; Doering CB; Lollar P; Spiegel PC
    Blood; 2021 May; 137(21):2981-2986. PubMed ID: 33529335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Frequency and epitope specificity of anti-factor VIII C1 domain antibodies in acquired and congenital hemophilia A.
    Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Jacquemin M; Krause M; Tiede A; Schwabe D; Lollar P; Königs C
    Blood; 2017 Aug; 130(6):808-816. PubMed ID: 28507083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Functional identification of factor VIII B domain regions in hepatocyte cells.
    Jun Z; Ming-Ming L; Qian-Qing Z; Yun-Hong W; Chong-Yang Z; Xin L
    Biochem Biophys Res Commun; 2020 Jun; 526(3):633-640. PubMed ID: 32248973
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction of tolerance to factor VIII inhibitors by gene therapy with immunodominant A2 and C2 domains presented by B cells as Ig fusion proteins.
    Lei TC; Scott DW
    Blood; 2005 Jun; 105(12):4865-70. PubMed ID: 15769892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains.
    Gharagozlou S; Sharifian RA; Khoshnoodi J; Karimi K; Milani M; Okita DK; Shokri F; Conti-Fine BM
    Thromb Haemost; 2009 May; 101(5):834-9. PubMed ID: 19404535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.